All In Biotech

Drug Trial Radar · NCT07905547

A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis

A Multi-center, Single-arm Phase IV Clinical Trial to Evaluate the Safety of Dupilumab in Adult Indian Patients With Moderate-to-severe Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

56

Planned (sponsor's estimate)

Start

Oct 28, 2026

Primary completion

Feb 7, 2027

Study completion Aug 2, 2028

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Oct 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will describe safety of dupilumab in adult participants with atopic dermatitis. It will also look at the improvement of atopic dermatitis signs and symptoms in these participants. The maximum study duration would be 32 weeks which includes the below: * Up to 28 days of screening period in which the doctor will assess if the participant can be recruited in this study * Treatment duration is 16 weeks * Follow up period: during which the participant will be followed for 12 weeks to check for any safety events. Visit frequency: The visit frequency will be every 4 weeks during the 16 weeks treatment duration and then 12 weeks after the last dose of the study treatment. Total number of visits will be 7.

Conditions

  • Atopic Dermatitis

Interventions

  • DupilumabDrug

    Each single-use pre-filled syringe with needle shield contains 300 mg dupilumab in 2 mL solution.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants who Experienced Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to Week 16

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.